FDA Advisory Committee Votes to Delay Myeloma Drug Approval

Drug Industry Daily
A A
The FDA’s Oncologic Drugs Advisory Committee voted 8 to 5 on Tuesday in favor of delaying the approval of Karyopharm Therapeutics’ NDA for selinexor, a multiple myeloma treatment, pending the results of a Phase 3 trial.

To View This Article:

Login

Subscribe To Drug Industry Daily